Redwood Grove Capital LLC Takes Position in Elanco Animal Health Incorporated $ELAN

Redwood Grove Capital LLC acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, Holdings Channel.com reports. The firm acquired 1,525,300 shares of the company’s stock, valued at approximately $37,538,000. Elanco Animal Health comprises approximately 9.5% of Redwood Grove Capital LLC’s portfolio, making the stock its biggest holding.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Elanco Animal Health in the second quarter valued at approximately $1,202,198,000. Primecap Management Co. CA bought a new stake in shares of Elanco Animal Health during the 2nd quarter worth $1,118,402,000. The Manufacturers Life Insurance Company bought a new stake in shares of Elanco Animal Health during the 2nd quarter worth $205,636,000. UBS Group AG grew its stake in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares during the last quarter. Finally, Sei Investments Co. grew its stake in Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock valued at $135,214,000 after buying an additional 4,975,721 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Up 2.8%

Shares of ELAN stock opened at $25.11 on Wednesday. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The stock has a fifty day moving average price of $24.58 and a 200 day moving average price of $24.01. The stock has a market cap of $12.55 billion, a P/E ratio of -61.25, a price-to-earnings-growth ratio of 1.46 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the previous year, the firm posted $0.26 EPS. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on ELAN shares. TD Cowen boosted their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. KeyCorp raised their price target on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Citigroup lifted their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Finally, UBS Group boosted their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average target price of $29.09.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington purchased 5,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was purchased at an average price of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the purchase, the director directly owned 131,451 shares in the company, valued at approximately $2,868,260.82. This trade represents a 3.95% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Shiv O’neill acquired 3,998 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were bought at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the completion of the acquisition, the insider directly owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. This represents a 4.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 63,198 shares of company stock worth $1,473,109 in the last 90 days. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.